All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
6-month update on the phase III VIALE-C trial
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Andrew Wei, The Alfred, Melbourne, AU, who provided information on the 6-month update of the phase III VIALE-C trial.
6-month update on the phase III VIALE-C trial
The current standard of care for elderly patients with AML is cytarabine (Ara-C), however, response rates are modest, and alternative therapeutic strategies are required. The VIALE-C study is evaluating venetoclax in combination with low-dose Ara-C for the treatment of elderly patients with AML. Here, Andrew Wei outlines the study design and patient responses to Ara-C + venetoclax vs Ara-C + placebo.
More about...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox